TickerFacts.

Company research / EXEL

Exelixis, Inc. (EXEL)

Build a valuation ↗↓ Download CSV

SEC name EXELIXIS, INC. · CIK 0000939767 · Nasdaq · Biological Products, (No Diagnostic Substances)

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends around Jan 1

For the year ended 2026-01-02 (fiscal 2025), Exelixis, Inc. reported revenue of $2.32B. Revenue grew 7.0% from the prior annual period. Over the twelve months to 2026-07-03, revenue was $2.44B.

Key ratios (year ended 2026-01-02, fiscal 2025)

37.6%
Operating margin
33.7%
Net margin
36.2%
Return on year-end equity
7.0%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2026-09-11

Headquarters locality: South San Francisco · View on map

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-07-03 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-07-03		2026-01-02, Fiscal 20252025-01-03, Fiscal 20242023-12-292022-12-302021-12-312021-01-01, Fiscal 20202020-01-03, Fiscal 20192018-12-282017-12-292016-12-31
Revenue$2.44B$2.32B$2.17B$1.83B$1.61B$1.43B$987.54M$967.77M$853.83M$452.48Mn/a
Cost of Revenue$85.67M$83.70M$76.22M$72.55M$57.91M$52.87M$36.27M$33.10M$26.35M$15.07Mn/a
R&D Expense$824.32M$825.00M$910.41M$1.04B$891.81M$693.72M$547.85M$336.96M$182.26M$112.17Mn/a
Operating Income$971.51M$872.19M$604.62M$170.88M$201.48M$286.67M$110.06M$369.47M$438.86M$165.91Mn/a
Depreciation & Amortization$28.30M$29.05M$28.80M$25.72M$20.88M$13.63M$9.14M$8.35M$4.92M$1.19Mn/a
EBITDA$999.81M$901.25M$633.42M$196.60M$222.36M$300.30M$119.20M$377.82M$443.77M$167.10Mn/a
Net Income$860.62M$782.57M$521.27M$207.76M$182.28M$231.06M$111.78M$321.01M$690.07M$154.23Mn/a
EPS (Diluted)n/a$2.78$1.76$0.65$0.56$0.72$0.35$1.02$2.21$0.49n/a
Total Assets$2.49B$2.84B$2.95B$2.94B$3.07B$2.62B$2.14B$1.89B$1.42B$655.29M$597.54M
Total Liabilities$650.47M$683.10M$703.49M$678.45M$583.06M$405.62M$258.22M$199.70M$134.83M$370.33M$508.22M
Long-Term Debtn/an/an/an/an/an/an/an/an/a$0$189.12M
Shareholders' Equity$1.84B$2.16B$2.24B$2.26B$2.49B$2.21B$1.88B$1.69B$1.29B$284.96M$89.32M
Cash & Equivalents$281.45M$482.49M$217.37M$262.99M$501.19M$647.17M$319.22M$266.50M$314.77M$183.16M$151.69M
Operating Cash Flow$1.18B$884.27M$699.97M$333.32M$362.61M$400.80M$208.98M$526.96M$415.72M$165.61Mn/a
Capital Expenditures$10.96M$8.43M$28.43M$40.47M$27.71M$54.23M$30.34M$12.83M$33.30M$21.14Mn/a
Free Cash Flow$1.17B$875.84M$671.54M$292.86M$334.91M$346.58M$178.64M$514.12M$382.42M$144.47Mn/a
Share Repurchases$1.11B$947.51M$652.03M$550.38M$0$0n/an/an/an/an/a
Shares Outstanding248.88M262.48M281.73M302.79M323.95M318.84M311.63M304.83M299.88M296.21M289.92M
Weighted Average Diluted Sharesn/a281.86M296.13M321.46M324.56M322.36M318.00M315.01M312.80M312.00Mn/a
EPS (Basic)n/a$2.88$1.80$0.65$0.57$0.73$0.36$1.06$2.32$0.52n/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView